Sansure Biotech Inc. (SHA:688289)

Market Cap	12.22B
Revenue (ttm)	1.54B
Net Income (ttm)	286.31M
Shares Out	574.18M
EPS (ttm)	0.49
PE Ratio	43.50
Forward PE	32.26
Dividend	0.53 (2.47%)
Ex-Dividend Date	Jun 11, 2025

Volume	5,137,606
Average Volume	5,799,443
Open	21.44
Previous Close	21.42
Day's Range	21.18 - 21.48
52-Week Range	16.44 - 26.36
Beta	0.68
RSI	65.75
Earnings Date	Aug 30, 2025

About Sansure Biotech

Sansure Biotech Inc. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments in China. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2008
• Employees: 2,346
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688289

Financial Performance

In 2024, Sansure Biotech's revenue was 1.46 billion, an increase of 44.78% compared to the previous year's 1.01 billion. Earnings were 275.60 million, a decrease of -24.23%.